title: When should low-molecular-weight heparin be monitored?
authors.affiliation: Clinical Pathology Section, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.
authors.forename: R B
authors.initials: RB
authors.lastname: Fairweather
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000465:Algorithms; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D019644:Arthroplasty, Replacement, Hip; D001780:Blood Coagulation Tests; D003937:Diagnosis, Differential; D016903:Drug Monitoring / Q000379:methods*; D006470:Hemorrhage / Q000139:chemically induced / Q000175:diagnosis; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D010338:Pathology, Clinical / Q000379:methods
chemical_list: D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight